Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
News Every Day |

Analysis: Berkshire’s bet a bright spot in gloomy year for Big Pharma stocks

November 18, 2020

By Lewis Krauskopf

NEW YORK (Reuters) – Berkshire Hathaway Inc’s <BRKa.N> new bet on the U.S. pharmaceutical industry signals hope for shares of large drug companies, which have lagged a broad market rally amid concern about efforts to rein in prescription drug prices.

Drug stocks largely outperformed on Tuesday, a day after Warren Buffett’s conglomerate, long underweight in the healthcare sector, revealed $5.7 billion of new investments in Abbvie Inc <ABBV.N>, Bristol-Myers Squibb Co <BMY.N>, Merck & Co <MRK.N> and Pfizer Inc <PFE.N>, whose vaccine has demonstrated effectiveness in late-stage studies against COVID-19.

“It’s a recognition of, ‘Hey, there’s some value there,’” said Walter Todd, chief investment officer at Greenwood Capital, whose funds hold shares of Pfizer, Merck and Eli Lilly <LLY.N>.

Pharma stocks also received a boost after the Nov. 3 U.S. elections made clear there would be no overwhelming Democratic sweep, an outcome some investors feared could prompt a major overhaul of drug pricing.

Still, many are reluctant to sound an all-clear on the industry, which is trading close to its biggest-ever valuation gap against the S&P 500 based on forward price-to-earnings ratios, according to Refinitiv Datastream.

Among the issues on investors’ minds is whether Democrats can secure a slim margin in the U.S. Senate if their candidates win run-off races in Georgia scheduled for January, a result that could spark volatility throughout the healthcare sector.

Beyond that, pharmaceutical stocks continue to face pressure from concerns over lawmakers’ efforts to bring down high drug prices, investors said.

“That is an area where you can quickly get to some sort of bipartisan agreement,” said Les Funtleyder, a healthcare portfolio manager at E Squared Capital.

So far in 2020, the S&P 500 pharmaceutical industry index <.SPLRCCARG> has gained 0.6%, versus an 11.7% gain for the overall S&P 500 <.SPX>, and an 8.8% gain for the S&P 500 healthcare sector <.SPXHC>.

Shares of the two biggest pure-play pharma companies by market value, Merck and Pfizer, have fallen 10% and 3%, respectively, this year.

“Big pharma names have underperformed, and look cheap relative to historical valuations and the market overall,” said Jim Shanahan, an Edward Jones analyst who covers Berkshire. “These are large, dominant companies in an industry that has demonstrated strong, long-term growth.”

Investors say pharma stocks have also lagged because many top-selling products are slated to lose patent protection in the coming years, including Abbvie’s blockbuster Humira.

“As you get within five years of patent expirations, people start to look and get more nervous about growth prospects,” said Marshall Gordon, senior healthcare analyst at Clearbridge Investments.

Another factor hurting pharma’s performance, said Jared Holz, healthcare equity strategist at Jefferies, is that the stock market currently is dominated on a given day by either a trade favoring big tech, stay-at-home stocks, or a trade favoring economically cyclical stocks.

Pharma does not fall into either of those categories, Holz said, so “they seem to underperform irrespective of what the broader markets are doing.”

At the same time, he said, the stocks “are trading at such a meaningful discount on an absolute and relative basis that they are intriguing almost solely due to that.”

(Reporting by Lewis Krauskopf; additional reporting by Jonathan Stempel; Editing by Ira Iosebashvili and Dan Grebler)




Read also

England chasing 192 to beat South Africa in third men's T20 – live!

Sheriffs bust defiant NYC bar in COVID-19 hotspot

Brad Stevens Not Sweating Exodus Of Top Players From Celtics Over Last Two Years



News, articles, comments, with a minute-by-minute update, now on Today24.pro




Today24.pro — latest news 24/7. You can add your news instantly now — here